FDBusiness.com

Nestlé Health Science, a Nestlé subsidiary dedicated to developing nutritional solutions for people with specific medical conditions, is investing SFr67 million (US$70 million, Eur61 million) in a new Product Technology Centre at Bridgewater, New Jersey, in the US. As part of Nestlé’s global R&D network, the facility will focus on developing innovative nutritional therapies that improve nutritional status and health outcomes for people in the US and other parts of the world. The Centre will open in 2016.

Nestlé Health Science, established four years ago, focuses on deepening the role of nutrition in healthcare, an area that is rich in innovation potential as we learn more about the roles of nutrients in addressing health needs.

Nestlé Health Science CEO Greg Behar says: “This investment reflects our commitment to leading the development of innovative nutritional therapies that change the course of health for people and patients in the US and globally. The new facility will house the latest technologies and people in the field, uniting our R&D and business teams in a region with strong life-science activity; it will enhance and accelerate the quality and speed to market of Nestlé Health Science’s innovations that improve nutritional status and health outcomes.”

The Bridgewater facility will be one of more than 30 Nestlé Product Technology Centres around the world, which have become key success factors in the continued growth and development of Nestlé as the world’s largest nutrition health and wellness company, with sales approaching $100 billion per year. These Centres provide a wide range of product-specific R&D, science and technical expertise; the Bridgewater Centre will deliver applied research, specialized technology, nutrition translation and innovative product development supporting Nestlé Health Science’s three main business areas: Consumer Care, Medical Nutrition and Novel Therapeutic Nutrition.